Strong Industry Recognition Science 37 has recently received the 2024 Global Company of the Year Award for Decentralized Clinical Trials and the Clinical Efficiency Innovation Award at the MedTech Breakthrough Awards, highlighting its leadership and reputation in the decentralized trial space, which can be leveraged for credibility in sales pitches.

Partnership Expansion The company’s partnership with the CGD Association of America demonstrates its active involvement in collaborative projects and expanding patient access solutions, presenting opportunities to propose tailored partnership or service enhancement ventures.

Leadership Evolution The appointment of a new CEO, Tyler Van Horn, in January 2025 indicates strategic leadership and potential shifts in company focus, opening avenues to discuss innovative solutions aligned with new executive initiatives.

Recent Funding Growth With a funding total of $69 million and revenues between $50 and 100 million, Science 37 shows strong financial backing and market traction, signaling a reliable partner open to investing in advanced clinical research technology or expanding existing solutions.

Technological and Market Leadership Science 37’s use of advanced tech stacks like AWS Lambda, Node.js, and Qualys positions it as a technology front-runner; pitching complementary tech integrations or security solutions could appeal to their focus on innovation and data security.